Compare Moderna, Inc. (MRNA) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Xylem, Inc. — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while Xylem, Inc. trades at $117.66 (market cap $28.67B). The key difference: Xylem, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.43% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | XYL | |
|---|---|---|
Market Cap | $23.60B | $28.67B |
Sector | Health | Industrials |
52-Week High | $81.80 | $152.95 |
52-Week Low | $22.36 | $106.34 |
Enterprise Value | $19.70B | $29.92B |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
